Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotechnology company Vaxil Bio (TSXV:VXL) has begun a preclinical program to test its COVID-19 vaccine candidate
  • The company first announced the discovery of a potential candidate in February, and now has non-GMP vaccine material on hand
  • Vaxil has already filed for a number of US patents to do with treating the virus
  • Today, the company applied for an additional patent in connection with COVID-19
  • Vaxil Bio (VXL) is down 2.78 per cent, and is currently trading for C$0.18 per share

Biotechnology company Vaxil Bio (TSXV:VXL) has begun a preclinical program to test its COVID-19 vaccine candidate. 

In February this year, the company announced its belief that it had identified a potential vaccine candidate for the virus.

The candidate is based on patent-protected signal peptide technology, using Vaxil’s proprietary VaxHit bioinformatics platform. It is also based on successful in vivo experiments, testing a tuberculosis signal peptide vaccine.

Finally, the company now has non-GMP vaccine material on hand, and can begin testing the efficacy of the candidate. 

In early March, Vaxil announced its applications for a US patent on a coronavirus vaccine. 

The patent would provide broad protection for novel vaccines, pharmaceutical compositions, and methods for treating and preventing infectious disease. In particular, the patent would protect the methods for producing a peptide vaccine against coronaviruses. 

Today, the company has applied for an additional patent in connection with COVID-19. 

Vaxil’s Chairman and CEO, David Goren, commented on the developments.

“This is a very exciting moment for us, as we begin our lab work, less than six weeks from the first discovery. We are pleased with the progress that we have made to date on the development of our potential COVID-19 vaccine. 

“During the following weeks, we will work to advance our preclinical research for the development of this much-needed vaccine. We look forward to sharing additional information as we progress through our research program,” David said. 

Vaxil Bio (VXL) is down 2.78 per cent to C$0.18 per share, as of 11:10am EST.

More From The Market Herald

" WELL Health NCIB suggests undervaluation

WELL Health has entered into an automatic share purchase plan to facilitate share repurchases.

" Best biotech stocks to buy in 2023

Innovation continues to drive the broader healthcare market, and the best biotech stocks are at the forefront of new developments and therapies to
Lifeist

" Lifeist to acquire the fast-growing ‘Zest’ brand

Lifeist Wellness (TSXV:LFST) has signed a share purchase agreement to acquire the Zest brand.

" Advancing environmental work at the Frances Creek barium project

Voyageur Pharmaceuticals (TSXV:VM) has finished environmental and geotechnical field work at its Frances Creek project site.